On 18th October, 2021 FDA issued a public notice stating it approves ZIMHI injection. ZIMHI injection as an additional option to treat opioid overdose around the world. ZIMHI(naloxone hydrochloride) is administered using a single-dose and its prefilled syringe delivers 5 mg of ZIMHI naloxone hydrochloride solution through intramuscular (in the muscle) or subcutaneous (under the skin) injection.
FDA had previously approved injectable naloxone hydrochloride(ZIMHI) products in 0.4 milligram(mg) and 2 milligram(mg) doses under the name – NARCAN. Naloxone hydrochloride ZIMHI (approved by US FDA),is a medicine which will be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone hydrochloride ZIMHI is administered quickly, it can counter the opioid overdose effects within minutes. A 5 milligram (mg) dose and 0.5 milliliter (ml) prefilled syringe of naloxone hydrochloride provides an additional option in the treatment of opioid overdoses.
Source: US FDA
